Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Cancer. 2014 Mar 13;120(12):1780–1786. doi: 10.1002/cncr.28648

TABLE 1.

Studies Included in the Pooled Analysis

Study Phase No. of Patients Chemotherapy Median TTP/PFS Median OS
Ko 200617 2 51 FDR gemcitabine + cisplatin 3.9 mo (TTP) 7.1 mo
Ko 200818 2 52 FDR gemcitabine + cisplatin + bevacizumab 6.6 mo (TTP) 8.2 mo
Javle 200919 2 50 Gemcitabine + capecitabine+ bevacizumab 5.8 mo (PFS) 4.8 mo
Fogelman 201120 2 50 FDR gemcitabine + oxaliplatin + bevacizumab 4.9 mo (PFS) 11.9 mo
Hill 201121 1 21 FDR gemcitabine + capecitabine + docetaxel 5.8 mo (PFS) 7.4 mo
Martin 201216 2 42 FDR gemcitabine + infusional 5-FU + bevacizumab 5.9 mo (PFS) 7.4 mo
Ko 201222 1 45 FDR gemcitabine + capecitabine 5.5 mo (TTP) 9.8 mo

Abbreviations: 5-FU, 5-fluorouracil; FDR, fixed dose rate; OS, overall survival; PFS, progression-free survival; TTP, time to disease progression.